Matthew Thompson

CIK 1740988 · Chief Medical Officer · last filed 2024-06-28

Matthew Thompson is a Chief Medical Officer who has filed 13 SEC Form 4 insider transactions across 2 companies since 2018. The most recent filing, for VVOS, was dated Jun 28, 2024.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

2

Total Filings

13

Lifetime Open-Market Net

$0

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
VVOS Director $0.57 $0 3 2024-06-28
ENDOLOGIX INC /DE/ (ELGX) Delisted Chief Medical Officer 78,966 $0 8 2020-02-04

Recent Filings

13 filings
Form 4 transactions across all companies, newest first.
Filed Symbol Action Net Shares Net $ Link
2024-06-28 VVOS Grant (A) $0 EDGAR
2022-12-28 VVOS Grant (A) $0 EDGAR
2021-08-10 VVOS Grant (A) $0 EDGAR
2020-08-14 Sell (S) −21,888 -$1.9K
2020-08-07 Disp (D) +27,016 -$239
2020-02-04 ENDOLOGIX INC /DE/ (ELGX) Delisted Mixed +1,131 -$783 EDGAR
2020-01-02 ENDOLOGIX INC /DE/ (ELGX) Delisted Mixed +41,733 -$8.9K EDGAR
2019-10-01 ENDOLOGIX INC /DE/ (ELGX) Delisted Mixed $0 EDGAR
2019-08-06 ENDOLOGIX INC /DE/ (ELGX) Delisted Grant (A) +30,433 $0 EDGAR
2019-05-10 ENDOLOGIX INC /DE/ (ELGX) Delisted Mixed +829 -$2.7K EDGAR
Showing 110 of 13
Page 1 of 2
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.